Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2021

10.09.2020 | COVID-19 Zur Zeit gratis

Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis

verfasst von: Benjamin Kwok, Shari B. Brosnahan, Nancy E. Amoroso, Ronald M. Goldenberg, Brooke Heyman, James M. Horowitz, Catherine Jamin, Akhilesh K. Sista, Deane E. Smith, Eugene Yuriditsky, Thomas S. Maldonado

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Coronavirus disease 2019 (COVID-19) is associated with increased rates of deep vein thrombosis (DVT) and pulmonary embolism (PE). Pulmonary Embolism Response Teams (PERT) have previously been associated with improved outcomes. We aimed to investigate whether PERT utilization, recommendations, and outcomes for patients diagnosed with acute PE changed during the COVID-19 pandemic. This is a retrospective cohort study of all adult patients with acute PE who received care at an academic hospital system in New York City between March 1st and April 30th, 2020. These patients were compared against historic controls between March 1st and April 30th, 2019. PE severity, PERT utilization, initial management, PERT recommendations, and outcomes were compared. There were more cases of PE during the pandemic (82 vs. 59), but less PERT activations (26.8% vs. 64.4%, p < 0.001) despite similar markers of PE severity. PERT recommendations were similar before and during the pandemic; anticoagulation was most recommended (89.5% vs. 86.4%, p = 0.70). During the pandemic, those with PERT activations were more likely to be female (63.6% vs. 31.7%, p = 0.01), have a history of DVT/PE (22.7% vs. 1.7%, p = 0.01), and to be SARS-CoV-2 PCR negative (68.2% vs. 38.3% p = 0.02). PERT activation during the pandemic is associated with decreased length of stay (7.7 ± 7.7 vs. 13.2 ± 12.7 days, p = 0.02). PERT utilization decreased during the COVID-19 pandemic and its activation was associated with different biases. PERT recommendations and outcomes were similar before and during the pandemic, and led to decreased length of stay during the pandemic.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099CrossRef Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099CrossRef
2.
Zurück zum Zitat Marginean A, Masic D, Brailovsky Y, Fareed J, Darki A (2020) Difficulties of managing submassive and massive pulmonary embolism in the era of COVID-19. JACC Case Rep 2:523 Marginean A, Masic D, Brailovsky Y, Fareed J, Darki A (2020) Difficulties of managing submassive and massive pulmonary embolism in the era of COVID-19. JACC Case Rep 2:523
3.
Zurück zum Zitat Bikdeli B, Madhavan MV, Jimenez D et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol 75(23):2950–2973CrossRef Bikdeli B, Madhavan MV, Jimenez D et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol 75(23):2950–2973CrossRef
4.
Zurück zum Zitat Schultz J, Giordano N, Zheng H et al (2019) EXPRESS: a multidisciplinary Pulmonary Embolism Response Team (PERT) - experience from a national multicenter consortium. Pulm Circ 9(3):2045894018824563CrossRef Schultz J, Giordano N, Zheng H et al (2019) EXPRESS: a multidisciplinary Pulmonary Embolism Response Team (PERT) - experience from a national multicenter consortium. Pulm Circ 9(3):2045894018824563CrossRef
5.
Zurück zum Zitat Rosovsky R, Zhao K, Sista A, Rivera-Lebron B, Kabrhel C (2019) Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost 3(3):315–330CrossRef Rosovsky R, Zhao K, Sista A, Rivera-Lebron B, Kabrhel C (2019) Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost 3(3):315–330CrossRef
6.
Zurück zum Zitat Rosovsky R, Chang Y, Rosenfield K et al (2019) Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J Thromb Thrombol 47(1):31–40CrossRef Rosovsky R, Chang Y, Rosenfield K et al (2019) Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J Thromb Thrombol 47(1):31–40CrossRef
7.
Zurück zum Zitat Chaudhury P, Gadre SK, Schneider E et al (2019) Impact of multidisciplinary Pulmonary Embolism Response Team availability on management and outcomes. Am J Cardiol 124(9):1465–1469CrossRef Chaudhury P, Gadre SK, Schneider E et al (2019) Impact of multidisciplinary Pulmonary Embolism Response Team availability on management and outcomes. Am J Cardiol 124(9):1465–1469CrossRef
8.
Zurück zum Zitat Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603CrossRef Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543–603CrossRef
9.
Zurück zum Zitat Panigada M, Bottino N, Tagliabue P et al (2020) Hypercoagulability of COVID-19 patients in Intensive Care Unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 18:1738CrossRef Panigada M, Bottino N, Tagliabue P et al (2020) Hypercoagulability of COVID-19 patients in Intensive Care Unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 18:1738CrossRef
11.
Zurück zum Zitat Yuriditsky E, Horowitz JM, Merchan C et al (2020) Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med 48:1319PubMed Yuriditsky E, Horowitz JM, Merchan C et al (2020) Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med 48:1319PubMed
12.
Zurück zum Zitat Liu S, Luo P, Tang M et al (2020) Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm 42(2):299–304CrossRef Liu S, Luo P, Tang M et al (2020) Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm 42(2):299–304CrossRef
15.
Zurück zum Zitat Sasangohar F, Jones SL, Masud FN, Vahidy FS, Kash BA (2020) Provider burnout and fatigue during the COVID-19 pandemic: lessons learned from a high-volume Intensive Care Unit. Anesth Analg 131(1):106–111CrossRef Sasangohar F, Jones SL, Masud FN, Vahidy FS, Kash BA (2020) Provider burnout and fatigue during the COVID-19 pandemic: lessons learned from a high-volume Intensive Care Unit. Anesth Analg 131(1):106–111CrossRef
16.
Zurück zum Zitat Singer BD, Jain M, Budinger GRS, Wunderink RG (2020) A Call for Rational Intensive Care in the era of COVID-19. Am J Respir Cell Mol Biol 63:132–133CrossRef Singer BD, Jain M, Budinger GRS, Wunderink RG (2020) A Call for Rational Intensive Care in the era of COVID-19. Am J Respir Cell Mol Biol 63:132–133CrossRef
17.
Zurück zum Zitat Rice TW, Janz DR (2020) In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc 17:787–789CrossRef Rice TW, Janz DR (2020) In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc 17:787–789CrossRef
18.
Zurück zum Zitat Gniadek TJ, Mallek J, Wright G et al (2020) Expansion of hospital-based blood collections in the face of COVID-19 associated national blood shortage. Transfusion 60(7):1470–1475CrossRef Gniadek TJ, Mallek J, Wright G et al (2020) Expansion of hospital-based blood collections in the face of COVID-19 associated national blood shortage. Transfusion 60(7):1470–1475CrossRef
Metadaten
Titel
Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis
verfasst von
Benjamin Kwok
Shari B. Brosnahan
Nancy E. Amoroso
Ronald M. Goldenberg
Brooke Heyman
James M. Horowitz
Catherine Jamin
Akhilesh K. Sista
Deane E. Smith
Eugene Yuriditsky
Thomas S. Maldonado
Publikationsdatum
10.09.2020
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2021
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02264-8

Weitere Artikel der Ausgabe 2/2021

Journal of Thrombosis and Thrombolysis 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.